Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $693.5 million.

  • Keros Therapeutics' Cash & Current Investments rose 3067.51% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.5 million, marking a year-over-year increase of 3067.51%. This contributed to the annual value of $559.9 million for FY2024, which is 6908.84% up from last year.
  • As of Q3 2025, Keros Therapeutics' Cash & Current Investments stood at $693.5 million, which was up 3067.51% from $690.2 million recorded in Q2 2025.
  • Keros Therapeutics' Cash & Current Investments' 5-year high stood at $720.5 million during Q1 2025, with a 5-year trough of $215.6 million in Q2 2022.
  • For the 5-year period, Keros Therapeutics' Cash & Current Investments averaged around $381.2 million, with its median value being $322.0 million (2023).
  • The largest annual percentage gain for Keros Therapeutics' Cash & Current Investments in the last 5 years was 36810.78% (2021), contrasted with its biggest fall of 1347.77% (2021).
  • Keros Therapeutics' Cash & Current Investments (Quarter) stood at $230.0 million in 2021, then rose by 21.3% to $279.0 million in 2022, then rose by 18.67% to $331.1 million in 2023, then skyrocketed by 69.09% to $559.9 million in 2024, then rose by 23.85% to $693.5 million in 2025.
  • Its Cash & Current Investments stands at $693.5 million for Q3 2025, versus $690.2 million for Q2 2025 and $720.5 million for Q1 2025.